Stifel downgraded Fulcrum Therapeutics to Hold from Buy with a price target of $6, down from $35, stating that the firm was "wrong on multiple fronts" related to FTX-6058 for sickle cell disease, or SCD. Despite FDA’s letter, the "obscure path forward," in addition to the possibility of a smaller addressable population, makes the firm "less sanguine on the drug," the analyst tells investors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics CMO Santiago Arroyo departs, Iain Fraser named interim
- Fulcrum Therapeutics expects cash to fund requirements into mid-2025
- Fulcrum Therapeutics reports Q4 EPS (50c), consensus (49c)
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
- Fulcrum Therapeutics downgraded at Morgan Stanley on clinical hold uncertainty
